A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia

Saved in:
Bibliographic Details
Published inAmerican journal of hematology Vol. 94; no. 11; pp. E291 - E294
Main Authors Tomlinson, Benjamin K., Tuscano, Joseph M., Abedi, Mehrdad, Welborn, Jeanna, Arora, Mili, O'Donnell, Robert T., Wun, Ted, Jonas, Brian A.
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.11.2019
Wiley Subscription Services, Inc
Subjects
Acute myeloid leukemia
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bortezomib
Bortezomib - administration & dosage
Bortezomib - adverse effects
Doxorubicin
Doxorubicin - administration & dosage
Doxorubicin - adverse effects
Doxorubicin - analogs & derivatives
Febrile Neutropenia - chemically induced
Female
Hematology
Humans
Hydroxyurea - administration & dosage
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute - drug therapy
Male
Middle Aged
Myeloid leukemia
Neoplastic Cells, Circulating
Polyethylene Glycols - administration & dosage
Polyethylene Glycols - adverse effects
Progression-Free Survival
Proteasome Inhibitors - administration & dosage
Proteasome Inhibitors - adverse effects
Targeted cancer therapy
Treatment Outcome
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Feature-1
ObjectType-Correspondence-3
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.25605